Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etrinabdione - VivaCell Biotechnology Espana

Next Previous
Drug Profile

Etrinabdione - VivaCell Biotechnology Espana

Alternative Names: EHP-101; VCE-004; VCE-004.8

Latest Information Update: 20 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VivaCell Biotechnology Espana
  • Developer Emerald Health Pharmaceuticals
  • Class Anti-inflammatories; Antifibrotics; Cannabinoids; Neuroprotectants; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Cannabinoid receptor CB2 agonists; Peroxisome proliferator-activated receptor gamma agonists; Protein phosphatase 2A stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Peripheral arterial disorders
  • Discontinued Diffuse scleroderma; Multiple sclerosis

Most Recent Events

  • 14 Jan 2025 VivaCell Biotechnology Espana plans phase-IIa CLAUDIA trial for Peripheral arterial disorders in Spain (NCT06774040),
  • 01 Jun 2024 Vivacell Biotechnology plans a phase IIa trial for Peripheral arterial disorders (Treatment-experienced) in Spain (PO, Solution) (CTIS2023-509452-34-00)
  • 11 Dec 2023 Phase-II clinical trials in Peripheral arterial disorders (PO), before December 2023 (VivaCell Biotechnology Espana pipeline, December 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top